Well again, that's not within the purview of the PMPRB. It's a Health Canada question, but it is actually moving in that direction to some degree, especially for the SAP drugs that they're trying to get onto the market and formalize their presence in Canada. They are contemplating working with the EMA, to a lesser extent the FDA, and I'm not sure about Australia, and accepting at face value the market authorization that's been granted in that country as a basis to grant it in Canada. It will still be on a case-by-case exceptional basis. I think it's mainly for those rare disease drugs that are on SAP currently, but it's a very good idea and it's one that's being adopted by Health Canada.
On November 6th, 2018. See this statement in context.